View in EDS HTML Full Text PDF Full Text

Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review.

Saved in:
Bibliographic Details
Title: Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review.
Authors: Valdivieso-Jiménez, Glauco (AUTHOR), Pino-Zavaleta, Dennis Anthony (AUTHOR), Campos-Rodriguez, Susan K. (AUTHOR), Ortiz-Saavedra, Brando (AUTHOR), Fernández, María F. (AUTHOR), Benites-Zapata, Vicente Aleixandre (AUTHOR)
Source: Psychiatric Quarterly. Dec2023, Vol. 94 Issue 4, p541-557. 17p.
Subjects: United States. Food & Drug Administration, Borderline personality disorder, Aripiprazole, Clinical trials, Antipsychotic agents, Patient safety
Abstract: Aripiprazole is an atypical antipsychotic medication, and its use in treating borderline personality disorder (BPD) is debatable because it is not FDA-approved for treating BPD. This study aimed to investigate the efficacy and safety of aripiprazole in patients with BPD. On July 2, 2021, the protocol (CRD42021256647) was registered in PROSPERO. PubMed, Scopus, Web of Science, Ovid-Medline, Embase, PsycINFO, and Cochrane (CENTRAL) were searched without regard for language or publication date. We also searched trial registries on ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform. Randomized clinical trials with adult patients diagnosed with BPD met the inclusion criteria. The Cochrane risk of bias for randomized trials (RoB-2) method was used to assess the quality of the included studies. We included two previously published randomized clinical trials. There were 76 patients with BPD, with 38, 12, and 26 assigned to the aripiprazole, olanzapine, and placebo groups, respectively. Most patients (88.16%) were females, with ages ranging from 22.1 to 28.14 yr. Aripiprazole has been proven to reduce anxiety, depression, anger, hostility, clinical severity, and obsessive–compulsive behavior, insecurity, melancholy, anxiety, aggressiveness/hostility, phobic anxiety, paranoid thinking, psychoticism, and somatization. The adverse effects were headache, insomnia, restlessness, tremor, and akathisia. The risk of bias was considerable in both trials, which is somewhat problematic considering that prejudice can lead to incorrect outcomes and conclusions. Aripiprazole has demonstrated encouraging outcomes in the treatment of patients with BPD. More randomized controlled studies are needed. [ABSTRACT FROM AUTHOR]
Copyright of Psychiatric Quarterly is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 173557040
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Valdivieso-Jiménez%2C+Glauco%22">Valdivieso-Jiménez, Glauco</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pino-Zavaleta%2C+Dennis+Anthony%22">Pino-Zavaleta, Dennis Anthony</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Campos-Rodriguez%2C+Susan+K%2E%22">Campos-Rodriguez, Susan K.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ortiz-Saavedra%2C+Brando%22">Ortiz-Saavedra, Brando</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fernández%2C+María+F%2E%22">Fernández, María F.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Benites-Zapata%2C+Vicente+Aleixandre%22">Benites-Zapata, Vicente Aleixandre</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Psychiatric+Quarterly%22">Psychiatric Quarterly</searchLink>. Dec2023, Vol. 94 Issue 4, p541-557. 17p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22United+States%2E+Food+%26+Drug+Administration%22">United States. Food & Drug Administration</searchLink><br /><searchLink fieldCode="DE" term="%22Borderline+personality+disorder%22">Borderline personality disorder</searchLink><br /><searchLink fieldCode="DE" term="%22Aripiprazole%22">Aripiprazole</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+trials%22">Clinical trials</searchLink><br /><searchLink fieldCode="DE" term="%22Antipsychotic+agents%22">Antipsychotic agents</searchLink><br /><searchLink fieldCode="DE" term="%22Patient+safety%22">Patient safety</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Aripiprazole is an atypical antipsychotic medication, and its use in treating borderline personality disorder (BPD) is debatable because it is not FDA-approved for treating BPD. This study aimed to investigate the efficacy and safety of aripiprazole in patients with BPD. On July 2, 2021, the protocol (CRD42021256647) was registered in PROSPERO. PubMed, Scopus, Web of Science, Ovid-Medline, Embase, PsycINFO, and Cochrane (CENTRAL) were searched without regard for language or publication date. We also searched trial registries on ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform. Randomized clinical trials with adult patients diagnosed with BPD met the inclusion criteria. The Cochrane risk of bias for randomized trials (RoB-2) method was used to assess the quality of the included studies. We included two previously published randomized clinical trials. There were 76 patients with BPD, with 38, 12, and 26 assigned to the aripiprazole, olanzapine, and placebo groups, respectively. Most patients (88.16%) were females, with ages ranging from 22.1 to 28.14 yr. Aripiprazole has been proven to reduce anxiety, depression, anger, hostility, clinical severity, and obsessive–compulsive behavior, insecurity, melancholy, anxiety, aggressiveness/hostility, phobic anxiety, paranoid thinking, psychoticism, and somatization. The adverse effects were headache, insomnia, restlessness, tremor, and akathisia. The risk of bias was considerable in both trials, which is somewhat problematic considering that prejudice can lead to incorrect outcomes and conclusions. Aripiprazole has demonstrated encouraging outcomes in the treatment of patients with BPD. More randomized controlled studies are needed. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Psychiatric Quarterly is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=173557040
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s11126-023-10045-8
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 17
        StartPage: 541
    Subjects:
      – SubjectFull: United States. Food & Drug Administration
        Type: general
      – SubjectFull: Borderline personality disorder
        Type: general
      – SubjectFull: Aripiprazole
        Type: general
      – SubjectFull: Clinical trials
        Type: general
      – SubjectFull: Antipsychotic agents
        Type: general
      – SubjectFull: Patient safety
        Type: general
    Titles:
      – TitleFull: Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Valdivieso-Jiménez, Glauco
      – PersonEntity:
          Name:
            NameFull: Pino-Zavaleta, Dennis Anthony
      – PersonEntity:
          Name:
            NameFull: Campos-Rodriguez, Susan K.
      – PersonEntity:
          Name:
            NameFull: Ortiz-Saavedra, Brando
      – PersonEntity:
          Name:
            NameFull: Fernández, María F.
      – PersonEntity:
          Name:
            NameFull: Benites-Zapata, Vicente Aleixandre
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: Dec2023
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-print
              Value: 00332720
          Numbering:
            – Type: volume
              Value: 94
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Psychiatric Quarterly
              Type: main
ResultId 1